Prosonix Enters Collaboration With Imperial College London to Accelerate Development of Engineered Combination Respiratory Medicines (Multi-component Particles™, MCPs™)

Prosonix Enters Collaboration With Imperial College London to Accelerate Development of Engineered Combination Respiratory Medicines (Multi-component Particles™, MCPs™) PR Newswire OXFORD, England, July 5, 2012 OXFORD, England, July 5, 2012 /PRNewswire/ -- Prosonix (Oxford, UK) announced that it has signed a Collaborative Research Agreement with Imperial College London to accelerate the development of engineered Multi-component Particles (MCPs™) as respiratory medicines. The collaboration will see Prosonix working closely with Dr Omar Usmani, an internationally recognised expert in respiratory diseases and inhaled drug delivery at the College's National Heart and Lung Institute (NHLI). Its aim is to develop a deeper understanding of how MCPs can be translated into new respiratory medicines with significant clinical benefits compared to existing combination formulations in chronic obstructive pulmonary disease (COPD) and asthma. Results from the Collaboration are intended to accelerate the development of Prosonix' PSX2000 MCP Series of novel combination medicines, with the aim of advancing one or more MCP candidates into formal preclinical/proof of concept studies in 2013. Prosonix' drug particle engineering approach and expertise has enabled the development of MCPs that combine two active respiratory drug molecules consistently in a pre-determined ratio in each and every particle in the formulation, without the need for additional excipients.